By Billy Candra 
Scientists and medics in Nottingham have unveiled a groundbreaking ultra-rapid method for genetically diagnosing brain tumours, slashing the classification time from a harrowing 6-8 weeks to as little as two hours. This transformative advancement, detailed in a new study published in Neuro-Oncology, promises to profoundly improve care for thousands of patients annually across the UK, offering quicker access to vital treatment decisions and alleviating immense patient anxiety. Developed collaboratively by scientists at the University of Nottingham and clinicians at Nottingham University Hospitals NHS Trust (NUH), this innovation represents a significant leap forward in precision medicine for one of the most aggressive and challenging cancers.
The Critical Need for Speed: Brain Tumour Statistics and Current Challenges
Brain tumours represent a formidable public health challenge. In the UK, an alarming 34 individuals are diagnosed with some form of brain tumour every day, amounting to over 12,000 new cases each year. Globally, the incidence varies, but the disease consistently ranks among the most deadly cancers, particularly for younger populations. The prognosis for many brain cancers remains bleak, with the average survival rate for the most aggressive forms often falling below a year. This grim reality underscores the urgent need for faster, more accurate diagnostic and treatment pathways.
Historically, diagnosing brain tumours has been a protracted and emotionally taxing process for patients and their families. Following an initial MRI scan to detect a suspicious mass, patients undergo surgery to obtain a tumour sample. This sample then embarks on a journey to centralised analysis facilities for complex genetic testing. These tests are crucial because, in recent years, the classification of brain tumours has shifted from purely visual pathological assessment to a more sophisticated understanding based on DNA and genetic abnormalities. This molecular characterisation is paramount for determining the tumour type, predicting its behaviour, and guiding targeted therapies.
However, the traditional process for these genetic analyses is notoriously slow, frequently taking 6-8 weeks, or even longer, to yield comprehensive results. This prolonged waiting period inflicts immense psychological distress on patients already grappling with a life-altering diagnosis. The uncertainty surrounding their specific tumour type and prognosis amplifies anxiety and fear, hindering their ability to plan for the future. Clinically, this delay is equally detrimental, as it postpones the initiation of critical treatments such as radiotherapy and chemotherapy. For rapidly progressing cancers like aggressive brain tumours, every week lost in diagnosis can significantly reduce the chances of successful treatment and ultimately impact survival outcomes. The psychological burden on patients and their families during this extended period of limbo is immeasurable, exacerbating an already traumatic experience.
A New Era of Rapid Diagnosis: The Nottingham Breakthrough
The innovation from Nottingham directly addresses this critical bottleneck, offering an unprecedented acceleration in diagnostic turnaround time. The team at NUH has already implemented this novel approach during 50 brain tumour surgeries, achieving a remarkable 100% success rate. Diagnostic results were consistently provided in under two hours from surgery, with detailed tumour classifications delivered within minutes of sequencing. Furthermore, the platform’s continuous sequencing capabilities allow for a fully integrated, comprehensive diagnosis within 24 hours.
Dr. Stuart Smith, a Neurosurgeon from the School of Medicine at the University of Nottingham and NUH, highlighted the profound impact of this speed: "Traditionally, the process of diagnosing brain tumours has been slow and expensive. Now, with this new technology, we can do more for patients because we can get answers so much more quickly, which will have a much bigger influence on clinical decision-making, in as little as two hours. Patients find waiting many weeks for results extremely difficult, and this adds to the anxiety and worry at what is already a very difficult time." He further elaborated on the potential for intraoperative decision-making: "This type of operation can be quite long, so potentially, a surgeon could be informed during surgery of the accurate diagnosis, which would then impact on the surgical strategy." This capability to inform surgical strategy during the operation itself represents a paradigm shift, allowing surgeons to adapt their approach based on real-time genetic insights into the tumour’s nature.
The Science Behind the Speed: Nanopore Sequencing and Methylation Analysis
The technological foundation of this breakthrough lies in advanced DNA sequencing methods. Professor Matt Loose, a biologist from the School of Life Sciences at the University of Nottingham, pioneered a method to sequence specific parts of human DNA at higher depth using portable sequencing devices developed by Oxford Nanopore Technologies. This innovation allows for the rapid examination of relevant regions of the human genome and the simultaneous sequencing of multiple DNA regions, thereby dramatically accelerating the entire diagnostic process.
Professor Loose’s work builds upon decades of advancements in genomics. While the first human genome sequencing in 2003 took years and billions of dollars, by 2018, sequencing an entire human genome could be achieved in about six months across multiple labs – a vast improvement, but still too slow for urgent clinical needs. The key to the Nottingham team’s speed is the targeted approach: "When we first were able to sequence an entire human genome in 2018, it took around five labs and six months to do, which obviously isn’t ideal when time is of the essence for a patient," Professor Loose explained. "This new method now allows us to choose the bits of DNA that we need to look at in order to answer specific questions, such as what type of tumour and how can it be treated. Combined with our later research where we were able to look at relevant parts of the human genome more quickly – then we now have a process where we can use ROBIN to create comprehensive classifications of tumours more quickly."
The system employs ROBIN, a sophisticated software tool operating on P2 PromethION nanopore sequencers. These devices function by detecting minute changes in electrical current as single molecules of DNA pass through a nanopore – an incredibly tiny hole – embedded in a membrane. Each unique DNA base (A, T, C, G) creates a characteristic electrical signal, allowing the sequencer to "read" the genetic code with astonishing speed.
Crucially, the Nottingham team focuses on a specific epigenetic modification called DNA methylation. "Once we have a sample from a patient, we can now quickly extract the DNA and look at the different properties to give us the information we need. Methylation is the one we are most interested in early on in this instance because that defines the tumour type," Professor Loose stated. Methylation patterns are chemical tags on DNA that don’t alter the genetic sequence itself but influence gene activity. In brain tumours, specific methylation patterns are highly indicative of particular tumour subtypes, making it a powerful diagnostic biomarker. The ability to rapidly analyse these patterns is central to the method’s unparalleled speed and accuracy. Once a tumour sample is removed during surgery, it is swiftly processed in the pathology lab for DNA extraction before being sent to Professor Loose’s team for sequencing and analysis.
Expert Perspectives and Clinical Significance
The medical community has greeted this innovation with considerable enthusiasm. Dr. Simon Paine, a Consultant Neuropathologist at NUH, underscored its revolutionary potential: "This new method of diagnosing brain tumours is going to be a game changer, it really is revolutionary. It not only increases the speed at which the results will be available, but the degree of accuracy of the diagnosis as well is incredible." The dual benefits of speed and enhanced accuracy are critical, as they allow for more precise and timely treatment decisions, moving away from a ‘one-size-fits-all’ approach towards truly personalised medicine.
The ability to receive diagnostic information within hours, potentially even during surgery, opens up unprecedented possibilities for clinical management. Surgeons could make immediate, informed decisions about the extent of tumour resection, the type of adjuvant therapy, or the need for additional procedures, directly influencing patient outcomes. This real-time feedback loop transforms the surgical theatre into a more dynamic and responsive environment.
Economic Advantages and Broader Implications
Beyond its clinical impact, the new diagnostic method also presents significant economic advantages. Professor Loose highlighted that the test is not only faster and more accurate but also cheaper than current methods. "Our calculations stand at around £450 per person, potentially less when scaled up," he revealed. "There are a few reasons for this. Our method can eliminate the need for four to five separate tests, reducing costs as a consequence as we are getting more information from the single test we do. Most importantly, it delivers results to the patients when they need them." This cost-effectiveness, coupled with improved patient outcomes, makes a compelling case for widespread adoption within the NHS. By consolidating multiple tests into a single, comprehensive assay, the system streamlines laboratory workflows, reduces reagent consumption, and minimises administrative overheads.
The Brain Tumour Charity, a leading patient advocacy organisation, has also lauded the breakthrough. Dr. Simon Newman, Chief Scientific Officer at the charity, emphasised the patient-centric benefits: "The delivery of an accurate diagnosis within hours of surgery will be transformative for all patients, ensuring rapid access to the optimal standard of care and – crucially – removing the uncertainty patients face when having to wait weeks for their diagnosis and prognosis." He further noted the broader systemic impact: "The potential to combine so many separate tests into one and deliver at a localised level is a game changer for driving equity of access to rapid and accurate molecular diagnosis." This localisation of advanced diagnostic capabilities is vital, as it reduces reliance on distant centralised labs, potentially shortening turnaround times further and ensuring that patients in all regions of the UK can benefit equally from this cutting-edge technology.
Paving the Way for Personalised Treatment and Research
The implications extend beyond routine diagnosis. Rapid, accurate genetic profiling is the cornerstone of personalised medicine, allowing clinicians to match patients to the most effective targeted therapies and clinical trials. Dr. Newman highlighted this crucial link, mentioning that "The BRAIN MATRIX Trial, funded by the Brain Tumour Charity, is now exploring how this technology can match patients to personalised clinical trials across the UK." This synergy between diagnostic innovation and therapeutic research accelerates the development and deployment of new treatments, offering hope for improved survival and quality of life.
The ability to rapidly characterise tumours genetically also holds immense value for research. It facilitates a deeper understanding of tumour biology, identifies new therapeutic targets, and allows for more efficient screening of potential drug candidates. This diagnostic platform could serve as a model for other cancer types or diseases where rapid, comprehensive genetic analysis is critical.
The Path Forward: National Rollout and Future Potential
The Nottingham team is now focused on scaling up this revolutionary testing method and securing its rollout across NHS Trusts nationwide. The goal is to make this advanced diagnostic capability accessible to every patient in the UK diagnosed with a brain tumour, thereby standardising and elevating the level of care. Such a national implementation would not only improve individual patient outcomes but also establish the UK as a leader in rapid, precision cancer diagnostics.
The success of this project also serves as a powerful testament to the collaborative power of academic research and clinical application. The close working relationship between the University of Nottingham’s scientific expertise and NUH’s clinical experience has been instrumental in translating cutting-edge genomic science into a tangible patient benefit.
In conclusion, the development of this ultra-rapid genetic brain tumour diagnosis method is a monumental achievement. By drastically reducing diagnostic waiting times, enhancing accuracy, and offering cost efficiencies, it stands to alleviate immense patient suffering, accelerate access to life-saving treatments, and propel the field of precision oncology forward. This innovation from Nottingham is not just a scientific triumph; it is a beacon of hope for thousands of brain tumour patients and their families, promising a future where faster answers lead to better lives.
